Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ministry of Health Labour and Welfare
Headquarters: Tokyo, Japan
Website: http://www.mhlw.go.jp/english/...
Year Founded: 2001
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Sep 25, 2023
Product Development
Sept. 25 Quick Takes: Novartis’ Lutathera meets primary for first-line GEP-NETs
Plus: Japan’s latest drug approvals and updates from Junshi, Adela, AbbVie, I-Mab, Novo, Valo, BridgeBio, GSK, Scynexis
BioCentury | Aug 22, 2023
Regulation
Aug. 21 Quick Takes: Pfizer’s Abrysvo granted maternal indication
Plus: Andreessen Horowitz co-leads $200M round for AI company Genesis, Leqembi closes in on Japan approval and more
BioCentury | Jun 10, 2023
Deals
June 9 Quick Takes: U.K. Treg play Quell finds first partner in AZ
Plus: Astellas submits first-in-class Claudin program in Japan and updates from Innolake and CMS
BioCentury | Jun 22, 2022
Deals
June 21 Quick Takes: Precision, Novartis in gene editing collaboration
Plus Galapagos acquires two companies, BioMarin gains an approval in Japan and updates from Merck & Co., BeiGene, Therorna, Acer and more
BioCentury | Jun 21, 2022
Regulation
June 20 Quick Takes: EMA reviewing BMS’s Breyanzi
Plus regulatory updates from Innovent and Chugai
BioCentury | Mar 29, 2022
Regulation
March 28 Quick Takes: Japan approvals include Sanofi’s Xenpozyme for rare disease
Plus more bad news for ALS and Biogen, Eagle acquiring Acacia, and more
BioCentury | Nov 30, 2021
Product Development
Nov. 29 Quick Takes: First TYK2 inhibitor to market on horizon?
Plus updates from NRx, Fennec, Merck & Co., Adagio
BioCentury | Oct 1, 2021
Finance
Sept. 30 Quick Takes: Advent closes €86M second fund
Data for Sanofi’s anti-OX40 mAb, plus TrialSpark’s $156M series C, Minerva’s next step toward schizophrenia submission and more
BioCentury | Sep 28, 2021
Product Development
Sept. 27 Quick Takes: Padcev approved in Japan
Acceleron rumors, Somatrogon delay, Keytruda in HCC, verdiperstat data and more
BioCentury | Mar 25, 2021
Regulation
March 24 Quick Takes: A first for Twist, Biotia and a refusal-to-file letter for Novo; plus Novartis’ radioligand, Zealand, four Japan approvals and more
Twist Bioscience Corp. (NASDAQ:TWST) said it and partner Biotia Inc. received emergency use authorization from FDA for the first hybridization capture-based next-generation sequencing SARS-CoV-2
Items per page:
1 - 10 of 95